Literature DB >> 11878818

Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.

F F Behar-Cohen1, A El Aouni, S Gautier, G David, J Davis, P Chapon, J M Parel.   

Abstract

The major problems associated with the use of corticosteroids for the treatment of ocular diseases are their poor intraocular penetration to the posterior segment when administered locally and their secondary side effects when given systemically. To circumvent these problems more efficient methods and techniques of local delivery are being developed. The purposes of this study were: (1) to investigate the pharmacokinetics of intraocular penetration of hemisuccinate methyl prednisolone (HMP) after its delivery using the transscleral Coulomb controlled iontophoresis (CCI) system applied to the eye or after intravenous (i.v.) injection in the rabbit, (2) to test the safety of the CCI system for the treated eyes and (3) to compare the pharmacokinetic profiles of HMP intraocular distribution after CCI delivery to i.v. injection. For each parameter evaluated, six rabbit eyes were used. For the CCI system, two concentrations of HMP (62.5 and 150mg ml(-1)), various intensities of current and duration of treatment were analyzed. In rabbits serving as controls the HMP was infused in the CCI device but without applied electric current. For the i.v. delivery, HMP at 10mg kg(-1)as a 62.5mg ml(-1)solution was used. The rabbits were observed clinically for evidence of ocular toxicity. At various time points after the administration of drug, rabbits were killed and intraocular fluids and tissues were sampled for methylprednisolone (MP) concentrations by high pressure liquid chromatography (HPLC). Histology examinations were performed on six eyes of each group. Among groups that received CCI, the concentrations of MP increased in all ocular tissues and fluids in relation to the intensities of current used (0.4, 1.0 and 2.0mA/0.5cm(2)) and its duration (4 and 10min). Sustained and highest levels of MP were achieved in the choroid and the retina of rabbit eyes treated with the highest current and 10min duration of CCI. No clinical toxicity or histological lesions were observed following CCI. Negligible amounts of MP were found in ocular tissues in the CCI control group without application of current. Compared to i.v. administration, CCI achieved higher and more sustained tissue concentrations with negligible systemic absorption. These data demonstrate that high levels of MP can be safely achieved in intraocular tissues and fluids of the rabbit eye, using CCI. With this system, intraocular tissues levels of MP are higher than those achieved after i.v. injection. Furthermore, if needed, the drug levels achieved with CCI can be modulated as a function of current intensity and duration of treatment. CCI could therefore be used as an alternative method for the delivery of high levels of MP to the intraocular tissues of both the anterior and posterior segments. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11878818     DOI: 10.1006/exer.2001.1098

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  17 in total

1.  Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Control Release       Date:  2012-01-27       Impact factor: 9.776

2.  Iodide iontophoresis as a treatment for dry eye syndrome.

Authors:  J Horwath-Winter; O Schmut; E-M Haller-Schober; A Gruber; G Rieger
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

Review 3.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

4.  Early effects of corneal collagen cross-linking by iontophoresis in ex vivo human corneas.

Authors:  Rita Mencucci; Stefano Ambrosini; Iacopo Paladini; Eleonora Favuzza; Carlotta Boccalini; Giulia Raugei; Gabriella Barbara Vannelli; Mirca Marini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-04       Impact factor: 3.117

5.  Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.

Authors:  S Kevin Li; Mark R Liddell; He Wen
Journal:  J Pharm Biomed Anal       Date:  2011-01-05       Impact factor: 3.935

6.  Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.

Authors:  Jae Hwan Jung; Bryce Chiang; Hans E Grossniklaus; Mark R Prausnitz
Journal:  J Control Release       Date:  2018-03-02       Impact factor: 9.776

7.  Examination of barriers and barrier alteration in transscleral iontophoresis.

Authors:  Sarah A Molokhia; Eun-Kee Jeong; William I Higuchi; S Kevin Li
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

8.  Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Authors:  Henry F Edelhauser; Jeffrey H Boatright; John M Nickerson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

9.  Iontophoretic transport of charged macromolecules across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  Int J Pharm       Date:  2010-01-05       Impact factor: 5.875

10.  Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina.

Authors:  Charlotte Andrieu-Soler; Mounia Halhal; Jeffrey H Boatright; Staci A Padove; John M Nickerson; Eva Stodulkova; Rachael E Stewart; Vincent T Ciavatta; Marc Doat; Jean-Claude Jeanny; Therèse de Bizemont; Florian Sennlaub; Yves Courtois; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2007-05-02       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.